67.96 USD
-0.55
0.80%
At close Mar 28, 4:00 PM EDT
After hours
67.96
+0.00
0.00%
1 day
-0.80%
5 days
-2.90%
1 month
4.84%
3 months
-13.26%
6 months
-18.62%
Year to date
-13.70%
1 year
-2.29%
5 years
304.52%
10 years
304.52%
 

About: Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Employees: 163

0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 25

36% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 55

14.94% more ownership

Funds ownership: 92.52% [Q3] → 107.46% (+14.94%) [Q4]

12% more funds holding

Funds holding: 186 [Q3] → 208 (+22) [Q4]

10% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]

7% more capital invested

Capital invested by funds: $4.16B [Q3] → $4.46B (+$301M) [Q4]

8% more call options, than puts

Call options by funds: $35.8M | Put options by funds: $33.3M

Research analyst outlook

We haven’t received any recent analyst ratings for ACLX.

Financial journalist opinion

Based on 3 articles about ACLX published over the past 30 days

Neutral
Business Wire
1 week ago
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare.
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
Neutral
GlobeNewsWire
1 week ago
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
Positive
Seeking Alpha
1 week ago
Arcellx Impressive Safety Data Leaves Doubts
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
Arcellx Impressive Safety Data Leaves Doubts
Negative
Zacks Investment Research
1 month ago
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to earnings of $0.42 per share a year ago.
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates
Neutral
Business Wire
1 month ago
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024. “2024 was a transformational year for Arcellx as our ASH data presentations for anito-cel, in partnership with Kite, continued to demonstrate anito-cel's diff.
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
Neutral
Business Wire
1 month ago
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s.
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
Positive
Zacks Investment Research
3 months ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
5 Biotech Breakthrough Stocks to Watch in 2025
Positive
Investors Business Daily
3 months ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma.
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Positive
Benzinga
3 months ago
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
On Sunday, Arcellx, Inc.  ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Neutral
Business Wire
3 months ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of.
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
Charts implemented using Lightweight Charts™